AOBiome Therapeutics is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases. Their proprietary product candidates harness a single strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria, or AOB, a human commensal with well-understood and well-characterized biochemical properties that are critical to human health.